{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-017226","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.925748+00:00","generated_at":"2026-05-16T09:21:50.053205+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt","bullets":["Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.","Three additional tranches up to $75M available upon achieving clinical, regulatory, and commercial milestones; final $25M at Hercules' discretion.","Maturity date January 1, 2030; proceeds support detalimogene BLA filing in H2 2026 and potential launch in 2027.","Non-dilutive capital strengthens balance sheet for planned BLA in BCG-unresponsive NMIBC with carcinoma in situ."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-017226","json":"https://secwatch.observer/filing/0001193125-26-017226.json","markdown":"https://secwatch.observer/filing/0001193125-26-017226.md","text":"https://secwatch.observer/filing/0001193125-26-017226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/0001193125-26-017226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/engn-20260120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:21:50.053205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}